How Much Does Aduhelm Cost?
By
Simon Spichak, MSc
| September 12th, 2022
How much does Aduhelm cost? Even if you can cover the expense, that doesn’t mean the drug is easy to get. Aduhelm costs an…
Managing Personality Changes in Dementia
By
Simon Spichak, MSc
| August 30th, 2022
While dementia leads to memory loss and makes it difficult to carry out everyday tasks, the disease also changes one’s personality. Experts share insights…
ADHD Drugs for Alzheimer’s Apathy?
By
Simon Spichak, MSc
| August 11th, 2022
Scientists in the UK found that ADHD drugs might be the answer to treating apathy in people with Alzheimer’s disease. At least one in…
Two FDA-Approved Drugs May Help Treat Alzheimer’s Symptoms
By
Simon Spichak, MSc
| July 21st, 2022
Scientists screened 595 FDA-approved drugs to see if they interfered with the activity of gene mutation ApoE4. Two of these — antidepressant imipramine and…
CMS Says No Aduhelm Coverage for Patients Outside Clinical Trials
By
Simon Spichak, MSc
| April 8th, 2022
The Centers for Medicare and Medicaid Services finalized its decision to limit the coverage of Alzheimer’s drug Aduhelm and future monoclonal antibodies. In February…
Eisai Seeks Accelerated Approval for Alzheimer’s Drug Lecanemab
By
Simon Spichak
| September 28th, 2021
Eisai’s investigational Alzheimer’s drug lecanemab appeared to erase amyloid plaques in 4/5 of trial participants and slow cognitive decline for people with early-stage Alzheimer’s…
FDA Speeds Up Process for Two More Anti-Amyloids
By
Alexandra Marvar
| June 24th, 2021
The FDA will hasten the review of two more new Alzheimer’s drug candidates, Eli Lilly & Co.’s donanemab and Biogen and Eisai’s lecanemab. Today,…